Navigation Links
Drug for Treatment of Heart Failure Does Not Improve Survival,,Compared to More Widely-used Medication

CHICAGO, May 1, 2007—The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.

Acute decompensated heart failure (ADHF; severe heart failure characterized by inability of the heart to maintain adequate blood circulation) remains a common cause of hospitalization worldwide, but appropriate treatment is not always clear. Dobutamine improves symptoms but has been associated with an increased risk of death and other cardiovascular events, according to background information in the article. In a previous study, secondary analyses indicated that the drug levosimendan was associated with lower risk of death compared to dobutamine.

Alexandre Mebazaa, M.D., Ph.D., of the Université Paris Diderot and Hospital Lariboisiére AP-HP, Paris, and colleagues with the SURVIVE trial (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) conducted a study in which the primary purpose of the trial was to assess long-term survival outcomes for 1,327 ADHF patients who received levosimendan or dobutamine. The trial was conducted at 75 centers in 9 countries and patients were randomized between March 2003 and December 2004. Patients received either intravenous levosimendan (n = 664) or intravenous dobutamine (n = 663).

The researchers found that during the 180 days after drug infusion, there were 173 deaths (26 percent) in the levosimendan group and 185 deaths in the dobutamine group (28 percent). There were no statistical differences between treatment groups for most secondary end points (all-cause death at 31 days, number of days alive and out of the hospital, patient global assessment, patient assessment of dyspnea (difficulty breathing) at 24 hours, and cardiovascular death at 180 days). C
'"/>




Page: 1 2

Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Rapid HIV Testing Increases Possibility of Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
Post Your Comments:
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
(Date:7/29/2014)... , July 29, 2014 Pfenex Inc. (NYSE MKT: ... initial public offering of 8,333,333 shares of its common  stock ... All of the common stock was offered by Pfenex. In ... purchase up to 1,250,000 additional shares of common stock at ... are traded on the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... results for the fiscal third quarter 2014 after the ... The Company will host a conference call for ... Central Time (10 a.m. Eastern Time). Investors may access ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... conferences: , Citi 2012 Global Healthcare Conference at ... , RBC Capital Markets, Healthcare Conference at 9:00 ... The sessions may be accessed through the Company,s ...
... 21, 2012  Acuo Technologies®, the leader in high-performance ... management and data migration, announces another year of ... achieved sales growth of over 90% from the ... from fiscal year end 2010.  The company signed ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Company's Market Leading Position 2
(Date:7/30/2014)... July 30, 2014 According to the Yeast ... is a comprehensive guide that will help candida sufferers get ... few weeks. This book uncovers to readers the truth about ... addition, inside this book, people will discover natural and safe ... such as itching, burning, and irritation of the vagina or ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive guide that teaches people how ... few weeks. The book uncovers to readers the horrible truth ... in its review that inside this book, people will learn ... such as inflammation, asthma, and nasal infections. , Nasal Polyps ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review recently ... men who want to discover how to increase their ... a few months. Inside this book, learners will discover a ... avoid the aches and pains. , Vkool reveals in its ... the reason why stretching and warming up is so important ...
(Date:7/30/2014)... 30, 2014 Neil Haley, the Total Tutor ... GJ Reynolds to find out about what is branding, how ... best brand. , Reynolds is an original founding member of ... Vi Millionaire, and CEO of Simply G Media. He has ... You!" and holds the distinction of completing the Dale Brown ...
(Date:7/30/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... therapy note templates. Healthcare providers can now create ... all while meeting the HIPPA security requirements.     , ... (EMR) consist of psychological intake forms, treatment plan ... SOAP and DAP note formats are also available. ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2
... LIVERMORE, Calif. , Feb. 1 The ... recently featured headline stories about a clinical study that is ... surprised by the attention this study is getting from the ... Officer of Halt Medical, Inc., a medical technology company headquartered ...
... could lead to false positives -- adding stress to ... unnecessary follow-up treatment and dietary restrictions. But the ... risk of mental retardation, disability or death outweigh the ... research published today in the February issue of the ...
... ... Santen Inc., as its 2010 president. , ... San Francisco (Vocus) -- Ophthalmic Women Leaders (OWL) has appointed ... , , ,Prior to her appointment as president, Gleeson previously served as chair of ...
... , ... solution to overcome the obstacle of health insurance. , ... (PRWEB) February 1, 2010 -- EasyToInsureME announces a new solution to ... are very afraid. This past week states like Virginia and Pennsylvania are already making laws ...
... A ... ... A report on pedestrian accident statistics released by Elmhurst Hospital Center shows that the number of ... report is being analyzed by New York personal injury attorneys to help their clients., ...
... , Feb. 10 Event With Celebrity Panel To Discuss ... The increased scrutiny of the fashion industry and its use of ultrathin ... say that the fashion industry is at least partially responsible for "girls, ... the Girl Scouts of the USA . , The nationwide survey, ...
Cached Medicine News:Health News:Benefits outweigh risks associated with newborn screening for disorder 2Health News:Ophthalmic Women Leaders (OWL) Names Pamela Gleeson, CFO Of Santen Inc., as 2010 President 2Health News:Recent Shoppers Face Health Insurance Obstacles 2Health News:Recent Shoppers Face Health Insurance Obstacles 3Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 2Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 2Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: